European Medicines Agency publishes two scientific articles outlining importance of early interactions as an opportunity to improve generation of evidence required for bringing innovation to patients

One article analyses importance of early advice for generation of robust evidence after authorisation, once a medicine is used in clinical practice and the other discusses how to best support developers who are using new digital technologies in medicines development programme.


European Medicines Agency